Particular history of hormonal therapies of menopause: a lived experience

Descripción del Articulo

The history of menopausal hormone therapies (THM) begins during the 1940s when the benefits of estrogen on the climacteric syndrome were recognized. Since then the THM have suffered permanent ups and downs alternating periods of great euphoria with periods of deep depression. After more than thirty...

Descripción completa

Detalles Bibliográficos
Autor: Campodonico-Garibaldi, Ítalo
Formato: artículo
Fecha de Publicación:2019
Institución:Instituto Nacional Materno Perinatal
Repositorio:Revista Peruana de Investigación Materno Perinatal
Lenguaje:español
OAI Identifier:oai:ojs.www.fracturae.com:article/109
Enlace del recurso:https://investigacionmaternoperinatal.inmp.gob.pe/index.php/rpinmp/article/view/109
Nivel de acceso:acceso abierto
Materia:Historia
Terapia hormonal
Menopausia
History
Hormone therapy
Menopause
Descripción
Sumario:The history of menopausal hormone therapies (THM) begins during the 1940s when the benefits of estrogen on the climacteric syndrome were recognized. Since then the THM have suffered permanent ups and downs alternating periods of great euphoria with periods of deep depression. After more than thirty years of prescription of non-opposite estrogens, a significant increased risk of cancer and endometrial hyperplasias was demonstrated. Estrogenoterapia was proscribed! A short walk proved that the addition of progestins offered effective protection, avoiding the risks of hyperplasia and endometrial cancer. Towards the end of the 20th century, the use of THM reaches its peak, with additional benefits attributed to the cardiovascular system, memory and cognitive processes, skin and skin and quality of life. The results of the WHI study, published in 2002, all went astray, pointing to a significant increase in the risks of coronary heart disease, stroke, venous embolism and breast cancer. As a consequence, the THM totally execrated. However, the reanalysis of the data showed, in women under 60 years of age, favorable effects of THM on coronary heart disease risk. More recent studies indicate that transdermally administered estrogens associated with non-MPA progestins do not increase the risks of stroke, venous thromboembolism and breast cancer; and, they have a strong impact on the quality of life of the users. Again the THM would be finding an adequate channel.
Nota importante:
La información contenida en este registro es de entera responsabilidad de la institución que gestiona el repositorio institucional donde esta contenido este documento o set de datos. El CONCYTEC no se hace responsable por los contenidos (publicaciones y/o datos) accesibles a través del Repositorio Nacional Digital de Ciencia, Tecnología e Innovación de Acceso Abierto (ALICIA).